Cardiol Therapeutics’ Cannabidiol Formulation Reduced Inflammation—Phase II Topline Data Ignites the Race to Treat Acute Myocarditis

A single‐digit p-value has rarely carried such freight. Cardiol Therapeutics Inc. (NASDAQ: CRDL | TSX: CRDL) this morning unveiled…